EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial

Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Tatsuya Toyama, Masahiro Kashiwaba, Shoichiro Ohtani, Naruto Taira, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Takuhiro Yamaguchi und 3 weitere

Breast Cancer · 2026

DOI: 10.1007/s12282-026-01862-3 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Breast Cancer, 2026. Verfasst von Hiroji Iwata und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, 1 Aza-Kawasumi, Mizuho-Cho, Miz…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Agents, Hormonal, Neoplasm Recurrence, Local. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously reported the 21-gene Oncotype DX® assay results from TransNEOS in patients enrolled in the phase 3 NEOS trial. However, the association between assay results and long-term prognosis has remained unclear.

Methods

Of the 296 patients registered in TransNEOS, 226 patients were enrolled in this study. Multigene assay results were categorized into three groups based on Recurrence Score® (RS): RS low < 11, RS intermediate 11–25, RS high > 25. Kaplan–Meier methods evaluated the association between RS results and DDFS and OS across treatments and clinical response to neoadjuvant endocrine treatment (NET).

Results

The clinical efficacy of NET was judged as CR, PR, and SD in 4 (1.8%), 113 (50%), and 109 (48.2%) patients, respectively. In the RS low and intermediate groups, no statistically significant difference in DDFS or OS was observed between the endocrine therapy (ET) alone group and the chemoendocrine therapy (CT + ET) group. In the RS high group, OS was significantly lower in the ET group compared to the CT + ET group (p = 0.037). Among patients in the RS high group who achieved CR + PR response to NET, there was no significant difference in OS between the CT + ET group and the ET alone group (p = 0.25). However, the number of events was limited, and the study may have been underpowered to detect a meaningful difference.

Conclusions

The need for chemotherapy in postmenopausal HR + , HER2- breast cancer patients might be further informed by integrating the results of the Oncotype DX test with the response to NET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Agents, HormonalNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleErb-b2 Receptor Tyrosine KinasesPostmenopausePrognosisReceptors, EstrogenMiddle AgedAgedBiomarkers, TumorKaplan-Meier Estimate

Stichwörter der Autor:innen

ER positiveHER2 negativeNeoadjuvant endocrine therapy (NET)Oncotype DXPostmenopausal breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenERBB2 protein, humanAntineoplastic Agents, HormonalBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, 1 Aza-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya City, Aichi Prefecture, 467-8601, Japan. hiwata0422@gma…
  • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shōgoin Kawaracho, Sakyo-Ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan.
  • Department of Breast and Endocrine Surgery, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-Ku, Kumamoto City, Kumamoto Prefecture, 860-8556, Japan.
  • Department of Breast Oncology, Gunma Prefectural Cancer Center, 617-1, Takabayashi Nishimachi, Ota City, Gunma Prefecture, 373-8550, Japan.
  • Department of Breast Surgery, Nagoya City University, Graduate School of Medical Sciences, 1 Aza-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya City, Aichi Prefecture, 467-8601, Japan.
  • Breast Surgery Center, Heartlife Hospital, 208 Iju, Nakagusuku Village, Nakagami District, Okinawa, Okinawa Prefecture, 901-2492, Japan.

Zitieren

APA

Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Kashiwaba, M., Ohtani, S., Taira, N., Sakai, T., Hasegawa, Y., Nakamura, R., Yamaguchi, T., Sakamaki, K., Russell, C. A., & Sugiyama, N. (2026). Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial. Breast Cancer. https://doi.org/10.1007/s12282-026-01862-3

Vancouver

Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, et al. Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial. Breast Cancer. 2026. doi:10.1007/s12282-026-01862-3

BibTeX
@article{Iwata2026,
  author = {Iwata, Hiroji and Masuda, Norikazu and Yamamoto, Yutaka and Fujisawa, Tomomi and Toyama, Tatsuya and Kashiwaba, Masahiro and Ohtani, Shoichiro and Taira, Naruto and Sakai, Takehiko and Hasegawa, Yoshie and Nakamura, Rikiya and Yamaguchi, Takuhiro and Sakamaki, Kentaro and Russell, Christy A and Sugiyama, Naoko},
  title = {Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial},
  journal = {Breast Cancer},
  year = {2026},
  doi = {10.1007/s12282-026-01862-3}
}
Kostenlos starten →